Profound closes $36-million offering

Executive Summary

• Profound Medical Corp. has closed a registered direct offering of 5,142,870 common shares at $7.00 per share, generating approximately $36 million in gross proceeds.
• The company intends to complete a subsequent private placement to certain Canadian purchasers on or before December 30, 2025, subject to necessary approvals including conditional approval from the Toronto Stock Exchange.
• Net proceeds will be used for the expansion of sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes.

Key Details

• Transaction Structure: Registered direct offering of common shares.
• Shares Issued: 5,142,870 common shares.
• Price Per Share: $7.00.
• Gross Proceeds: Approximately $36 million (before fees and expenses).
• Warrant Coverage: None (straightforward equity investment).
• Placement Agent: Konik Capital Partners LLC, a division of T.R. Winston and Company LLC, acted as the exclusive placement agent.
• Use of Proceeds: Expansion of sales and marketing, working capital, research and development, strategic transactions, and general corporate purposes.
• Regulatory Basis: Offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-291516), declared effective by the SEC on December 4, 2025.
• Subsequent Private Placement:
  • Target: Certain Canadian purchasers.
  • Expected Closing: On or prior to December 30, 2025.
  • Conditions: Subject to receiving all necessary approvals, including conditional approval from the Toronto Stock Exchange.
  • Restrictions: No securities will be sold to U.S. purchasers in the private placement.

Notable Quotes

• None provided in the text.